MEI Pharma, Inc. (MEIP)

[value1008]

MEIP has been getting terrific clinical results with Pracinostat in combo with azacitidine.... rest of the pipeline looks like it's coming along nicely..... Some big money and better analyst names are standing up for this one:

Notoriously hard-to-please analyst Jon Aschoff of Brean Capital has a Price Target of $16 on MEIP (made last July, reiterated on Dec. 9 after the ASH presentation), and savvy analyst Daniel Brims of Cantor Fitzgerald has a PT of $14, reiterated on 12/23/14 well after the share-offering closed. These are not outlandish price-targets for MEIP, which already briefly touched a shareprice of $13.98 back in March 2014.

Point72 Asset Management took big position in MEIP with 2.4M shares since the Dec. share-offering; Fidelity holds 2.9M shares; veteran biotech investor Sam Isaly's OrbiMed has over 1.9M shares. Visium, et al., are also holders of sizeable number of shares.

BofA/MLynch led the recent share-offering in Dec.